Lilly Halts Trials Of PPAR Alpha Agonist After Preclinical Safety Signal
Phase II clinical trials of the atherosclerosis treatment candidate LY674 were halted after a primate study showed fatty liver deposits.
Phase II clinical trials of the atherosclerosis treatment candidate LY674 were halted after a primate study showed fatty liver deposits.